Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice

被引:7
|
作者
Goswamee, Priyodarshan [1 ]
Rice, Remington [2 ]
Leggett, Elizabeth [1 ]
Zhang, Fan [2 ]
Manicka, Sofia [2 ]
Porter, Joseph H. [2 ]
McQuiston, Rory [1 ]
机构
[1] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23284 USA
[2] Virginia Commonwealth Univ, Coll Humanities & Sci, Dept Psychol, Richmond, VA USA
关键词
Ketamine; (2R; 6R)-Hydroxynorketamine; Medial prefrontal cortex; Nucleus reuniens; Spatial working; Memory; Cognition; Electrophysiology; Optogenetics; ANTIDEPRESSANT ACTIONS; THALAMUS; INTERNEURONS; ANTAGONIST; MECHANISMS; DEPRESSION; LONG;
D O I
10.1016/j.neuropharm.2022.108965
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Acute cognitive impairment and abuse potential of ketamine incentivizes the search for alternatives to ketamine for clinical management of treatment-resistant depression. Recently, (2R,6R) hydroxynorketamine ((2R,6R)-HNK), a metabolite of ketamine, has shown promise due to its reported lack of ketamine-like reinforcing properties. Nonetheless, the effect of (2R,6R)-HNK on cognition has not been reported.Method: Adult male mice were placed in a Y-maze to measure spatial working memory (SWM) 24 h after treatment with either a single or repeated subanesthetic dose of (2R,6R)-HNK or ketamine. To determine the effect of the drug regimens on synaptic mechanisms in neural circuits deemed critical for SWM, we conducted patch-clamp electrophysiological recordings from neurons in the midline thalamic nucleus reuniens (RE) in response to optogenetic stimulation of medial prefrontal cortex (mPFC) inputs in acutely prepared brain slices.Results: Single or repeated treatment with a 10 mg/kg dose of either drug did not impact performance in a Ymaze. However, single administration of a 1/2-log higher dose (32 mg/kg) of ketamine significantly reduced SWM. The same dose of (2R,6R)-HNK did not produce SWM deficits. Interestingly, repeated administration of either drugs at the 32 mg/kg had no effect on SWM performances. Concomitant to these effects on SWM, only single injection of 32 mg/kg of ketamine was found to increase the mPFC-driven action potential firing activity in the RE neurons. Conversely, both single and repeated administration of the 32 mg/kg dose of (2R,6R)-HNK but not ketamine, increased the input resistance of the RE neurons. Conclusion: Our results indicate that acute treatment of ketamine at 32 mg/kg increases mPFC-driven firing activity of RE neurons, and this contributes to the ketamine-mediated cognitive deficit. Secondly, sub-chronic treatment with the same dose of ketamine likely induces tolerance. Although single or repeated administration of the 32 mg/kg dose of (2R,6R)-HNK can alter intrinsic properties of RE neurons, this dose does not produce cognitive deficit or changes in synaptic mechanism in the RE. This article is part of the special Issue on 'Stress, Addiction and Plasticity'.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
    Jordi Bonaventura
    Juan L. Gomez
    Meghan L. Carlton
    Sherry Lam
    Marta Sanchez-Soto
    Patrick J. Morris
    Ruin Moaddel
    Hye Jin Kang
    Panos Zanos
    Todd D. Gould
    Craig J. Thomas
    David R. Sibley
    Carlos A. Zarate
    Michael Michaelides
    Molecular Psychiatry, 2022, 27 : 4144 - 4156
  • [42] Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine
    Shaffer, Christopher L.
    Dutra, Jason K.
    Tseng, Wei Chou
    Weber, Mark L.
    Bogart, Luke J.
    Hales, Katherine
    Pang, Jincheng
    Volfson, Dmitri
    Ende, Christopher W. Am
    Green, Michael E.
    Buhl, Derek L.
    NEUROPHARMACOLOGY, 2019, 153 : 73 - 81
  • [43] Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
    Bonaventura, Jordi
    Gomez, Juan L.
    Carlton, Meghan L.
    Lam, Sherry
    Sanchez-Soto, Marta
    Morris, Patrick J.
    Moaddel, Ruin
    Kang, Hye Jin
    Zanos, Panos
    Gould, Todd D.
    Thomas, Craig J.
    Sibley, David R.
    Zarate, Carlos A., Jr.
    Michaelides, Michael
    MOLECULAR PSYCHIATRY, 2022, 27 (10) : 4144 - 4156
  • [44] What Are the Causes for Discrepancies of Antidepressant Actions of (2R, 6R)-Hydroxynorketamine?
    Hashimoto, Kenji
    Shirayama, Yukihiko
    BIOLOGICAL PSYCHIATRY, 2018, 84 (01) : E7 - E8
  • [45] Is the History Repeated? Can (2R, 6R)-Hydroxynorketamine be Another Antidepressant?
    Chaki, Shigeyuki
    Yamaguchi, Jun-ichi
    JOURNAL OF EXPERIMENTAL NEUROSCIENCE, 2018, 12
  • [46] Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects
    Pham, T. H.
    Defaix, C.
    Xu, X.
    Deng, S. X.
    Landry, D. W.
    Brachman, R. A.
    Denny, C. A.
    Gardier, A. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1000 - S1001
  • [47] Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice
    Goswami, Nidhi
    Aleem, Mohd
    Manda, Kailash
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2023, 50 (02) : 169 - 177
  • [48] Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice
    Hillhouse, Todd M.
    Partridge, Kaitlyn J.
    Garrett, Patrick I.
    Honeycutt, Sarah C.
    Porter, Joseph H.
    PLOS ONE, 2024, 19 (04):
  • [49] Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function
    Lumsden, Eric W.
    Troppoli, Timothy A.
    Myers, Scott J.
    Zanos, Panos
    Aracava, Yasco
    Kehr, Jan
    Lovett, Jacqueline
    Kim, Sukhan
    Wang, Fu-Hua
    Schmidt, Staffan
    Jenne, Carleigh E.
    Yuan, Peixiong
    Morris, Patrick J.
    Thomas, Craig J.
    Zarate, Carlos A., Jr.
    Moaddel, Ruin
    Traynelis, Stephen F.
    Pereira, Edna F. R.
    Thompson, Scott M.
    Albuquerque, Edson X.
    Gould, Todd D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (11) : 5160 - 5169
  • [50] A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R, 6R)-hydroxynorketamine and MK-801
    Morris, Patrick J.
    Burke, Richard D.
    Sharma, Alok K.
    Lynch, Daniel C.
    Lemke-Boutcher, Leslie E.
    Mathew, Shiny
    Elayan, Ikram
    Rao, Deepa B.
    Gould, Todd D.
    Zarate Jr, Carlos A.
    Zanos, Panos
    Moaddel, Ruin
    Thomas, Craig J.
    NEUROTOXICOLOGY AND TERATOLOGY, 2021, 87